Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
3 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Alpha Cognition Inc.’s names, not what it holds today.
Patents granted
3
3 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and 1 in 2023
Applications published
8
4 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Alpha Cognition Inc. its own name
named as the applicant on its applications, in CA
8 publishedALPHA COGNITION INC. its own name
CA, as the owner printed on each patent
0 published
Newest grantseach row opens the USPTO’s own copy
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Oct 16, 2025 | 2025/0320223 | AMORPHOUS SOLID FORMS OF ALPHA-1062 GLUCONATE | Pharmaceuticals | Alpha Cognition Inc. |
| Aug 7, 2025 | 2025/0248941 | COATED TABLETS FOR PH-DEPENDENT RELEASE OF BENZGALANTAMINE | Pharmaceuticals | Alpha Cognition Inc. |
| Mar 20, 2025 | 2025/0092105 | GRANULIN/EPITHELIN MODULES AND COMBINATIONS THEREOF TO TREAT NEURODEGENERATIVE DISEASE | Pharmaceuticals | Alpha Cognition Inc. |
| Mar 20, 2025 | 2025/0092055 | SOLID FORMS OF ALPHA-1062 GLUCONATE | Pharmaceuticals | Alpha Cognition Inc. |
| Sep 12, 2024 | 2024/0299407 | ALPHA-1062 FOR TREATING TRAUMATIC BRAIN INJURY | Pharmaceuticals | Alpha Cognition Inc. |
| Aug 1, 2024 | 2024/0252509 | SELF-PRESERVING COMPOSITIONS AND MULTI-USE DISPENSERS FOR ADMINISTERING ALPHA-1062 | Pharmaceuticals | Alpha Cognition Inc. |
| Dec 28, 2023 | 2023/0416267 | SOLID FORMS OF ALPHA-1062 GLUCONATE | Pharmaceuticals | Alpha Cognition Inc. · patent 12,157,743 granted from it |
| Jul 14, 2022 | 2022/0220121 | SOLID FORMS OF ALPHA-1062 GLUCONATE | Pharmaceuticals | Alpha Cognition Inc. · patent 11,795,176 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 6.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.